A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
Price : $35 *
At a glance
- Drugs Duvelisib (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms SYNCHRONY
- Sponsors Infinity Pharmaceuticals; Verastem Oncology
- 31 Aug 2018 Biomarkers information updated
- 03 May 2018 According to a Verastem Oncology media release, Verastem changed its name to Verastem Oncology.
- 22 Dec 2016 Status changed from recruiting to discontinued.